2024-04-29 08:42Financial Performance - The company reported a continuous growth in revenue, with a year-on-year increase of 15% in the last fiscal year, reaching approximately CNY 10 billion[24]. - In 2023, the company's revenue reached RMB 26,199,409 thousand, a slight increase from RMB 26,026,164 thousand in 2022, while the cost of sales was RMB (4,989,877) thousand compared to RMB (4,487,616) thousand in the previous year[25]. - Gross profit for 2023 was RMB 21,209,532 thousand, down from RMB 21,538,548 thousand in 2022, indicating a decrease of approximately 1.5%[25]. - The net profit attributable to the parent company was RMB 2,331,939 thousand in 2023, a decrease of 8.3% from RMB 2,543,570 thousand in 2022[25]. - The total profit for the year, including discontinued operations, was RMB 5,097,398 thousand, slightly up from RMB 5,002,618 thousand in 2022[25]. - The company reported a pre-tax profit of RMB 5,409,906 thousand for 2023, compared to RMB 5,214,869 thousand in 2022, showing a growth of approximately 3.8%[25]. - The company recorded revenue of approximately RMB 26,199.41 million, an increase of about 0.7% compared to the same period last year[59]. - Profit attributable to equity holders of the parent company was approximately RMB 2,331.94 million, a decrease of about 8.3% year-on-year[59]. - The company’s total profit for the year 2023 was RMB 5,097,398 thousand, slightly up from RMB 5,002,618 thousand in 2022, representing an increase of about 1.89%[175]. - The company’s financial costs for 2023 were RMB (495,237) thousand, compared to RMB (429,494) thousand in 2022, reflecting an increase of approximately 15.34%[175]. Research and Development - The innovative drug 福可維 (Anlotinib Hydrochloride Capsules) received regulatory approval in May 2018, contributing significantly to the company's oncology product line[17]. - The company has successfully developed a pipeline of innovative drugs, including 安尼可 (Pamiparib Injection) and 亿立舒 (Aibolizumab Injection), which are expected to drive future growth[5]. - Research and development expenses for 2023 were RMB (4,402,973) thousand, an increase from RMB (4,164,498) thousand in 2022, reflecting a focus on innovation[25]. - The group has 43 innovative drug candidates in the oncology field at clinical stages, including five in the listing application stage and 13 in Phase II trials, with expectations of seven innovative drugs and nine biosimilars being approved from 2024 to 2026[36]. - The group is actively developing D-1553, a KRAS G12C inhibitor, with plans for multiple clinical trials and a potential market launch in the coming years[36]. - The company aims to enhance R&D efficiency and quality in four major therapeutic areas: oncology, liver disease, respiratory, and surgical/pain relief[61]. - The company has 145 products under development, including 60 oncology drugs and 67 Class I innovative products[74]. Market Position and Strategy - The company has been recognized as one of the "Top 50 Global Pharmaceutical Companies" for five consecutive years from 2019 to 2023, highlighting its strong market position[16]. - The company plans to expand its market presence internationally, leveraging its strong R&D capabilities and established production bases across China[6]. - The company is committed to enhancing its market position through strategic initiatives, including potential mergers and acquisitions, to drive growth in a competitive landscape[33]. - The company is focused on business development and expanding its operational capabilities through strategic partnerships and collaborations[157]. - The company is actively involved in mergers and acquisitions, with a focus on expanding its market presence and enhancing its product offerings[156]. Corporate Governance - The company adheres to high standards of corporate governance, ensuring accountability and promoting shareholder interests[86]. - The board consists of seven executive directors, including the chairperson and CEO, and five independent directors[91]. - Independent directors account for more than one-third of the board, providing valuable independent perspectives and judgments[92]. - The board has established various committees, including an executive committee, audit committee, remuneration committee, nomination committee, and ESG committee[90]. - The company has a structured approach to corporate governance, including the formulation and review of governance policies and practices[93]. - The company emphasizes the importance of independent directors, with those serving over nine years requiring additional disclosure for re-election[95]. Environmental, Social, and Governance (ESG) Initiatives - The company achieved a total of 651 ESG indicators managed through its digital platform, covering all key member enterprises' ESG key performance management[83]. - The company was recognized as a "National Green Factory" and "Provincial Green Factory" for its commitment to building an environmentally friendly enterprise[84]. - The company is focused on ESG initiatives, with plans to invest 5 million in sustainability projects over the next two years[161]. - The ESG strategy emphasizes "CARE," focusing on disease treatment, pharmaceutical accessibility, environmental friendliness, and win-win relationships[104]. - The company actively engaged in social responsibility initiatives, contributing to disaster relief, rural revitalization, and health equity[84]. Financial Position and Assets - The total assets of the company as of 2023 amounted to RMB 63,604,819 thousand, while total liabilities were RMB (25,434,866) thousand, resulting in net assets of RMB 38,169,953 thousand[25]. - The company maintained a strong liquidity position with cash and bank balances of approximately RMB 94,518.8 million as of December 31, 2023, down from RMB 120,662.2 million as of December 31, 2022[77]. - The asset-to-liability ratio improved to approximately 40.0% as of December 31, 2023, from 40.8% as of December 31, 2022[80]. - The company’s total equity increased to RMB 38,169,953 as of December 31, 2023[126]. - The company’s total current assets decreased to RMB 23,805,531 thousand in 2023 from RMB 25,934,905 thousand in 2022, a decline of approximately 8.2%[178]. Shareholder Information - The company declared an interim dividend of HKD 0.02 per share, totaling approximately HKD 367,985,000 (equivalent to about RMB 332,324,000)[123]. - The board proposed a final dividend of HKD 0.03 per share for the fiscal year ending December 31, 2023, subject to shareholder approval[123]. - The company maintained a public shareholding ratio of over 25% throughout the year[150]. - The company has a total of 2,280,754,761 shares held by Ms. Xie Qirun, representing approximately 12.13% of the issued share capital[138]. - The company has implemented a share buyback plan with a total budget of up to HKD 1 billion, of which HKD 141.42 million was utilized for share repurchases and incentive share purchases by December 31, 2023[81].